tradingkey.logo

tradingkey.logo
āļ„āđ‰āļ™āļŦāļē


MediciNova Inc

MNOV
āđ€āļžāļīāđˆāļĄāļĨāļ‡āđƒāļ™āļĢāļēāļĒāļāļēāļĢāļ•āļīāļ”āļ•āļēāļĄ
1.395USD
-0.005-0.36%
āļ›āļīāļ” 11-13 16:00ET
68.91MāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
āļ‚āļēāļ”āļ—āļļāļ™P/E TTM

āđ€āļāļĩāđˆāļĒāļ§āļāļąāļš MediciNova Inc āļšāļĢāļīāļĐāļąāļ—

MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.

MediciNova Inc āđ‚āļ›āļĢāđ„āļŸāļĨāđŒ


āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™MNOV
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—MediciNova Inc
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļDec 01, 2006
āļ‹āļĩāļ­āļĩāđ‚āļ­Iwaki (Yuichi)
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™13
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒOrdinary Share
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Dec 01
āļ—āļĩāđˆāļ­āļĒāļđāđˆ4275 Executive Square
āđ€āļĄāļ·āļ­āļ‡LA JOLLA
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNASDAQ OMX - NASDAQ BASIC
āļ›āļĢāļ°āđ€āļ—āļĻUnited States of America
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ92037
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ18583731500
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://medicinova.com/
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™MNOV
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļDec 01, 2006
āļ‹āļĩāļ­āļĩāđ‚āļ­Iwaki (Yuichi)

āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—āļ‚āļ­āļ‡ MediciNova Inc


āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Dr. Yuichi Iwaki, M.D., Ph.D.
Dr. Yuichi Iwaki, M.D., Ph.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
1.09M
--
Dr. Kazuko Matsuda, M.D., Ph.D.
Dr. Kazuko Matsuda, M.D., Ph.D.
Senior Vice President, Chief Medical Officer, Director
Senior Vice President, Chief Medical Officer, Director
323.00K
--
Mr. Hideki Nagao
Mr. Hideki Nagao
Independent Director
Independent Director
--
--
Mr. Hideki Nagao
Mr. Hideki Nagao
Independent Director
Independent Director
--
--
Ms. Carolyn D. Beaver
Ms. Carolyn D. Beaver
Independent Director
Independent Director
--
--
Dr. David H. Crean, Ph.D.
Dr. David H. Crean, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Jason J. Kruger, CPA
Mr. Jason J. Kruger, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
--
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Dr. Yuichi Iwaki, M.D., Ph.D.
Dr. Yuichi Iwaki, M.D., Ph.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
1.09M
--
Dr. Kazuko Matsuda, M.D., Ph.D.
Dr. Kazuko Matsuda, M.D., Ph.D.
Senior Vice President, Chief Medical Officer, Director
Senior Vice President, Chief Medical Officer, Director
323.00K
--
Mr. Hideki Nagao
Mr. Hideki Nagao
Independent Director
Independent Director
--
--
Mr. Hideki Nagao
Mr. Hideki Nagao
Independent Director
Independent Director
--
--
Ms. Carolyn D. Beaver
Ms. Carolyn D. Beaver
Independent Director
Independent Director
--
--
Dr. David H. Crean, Ph.D.
Dr. David H. Crean, Ph.D.
Chief Business Officer
Chief Business Officer
--
--

āļ„āļģāļ–āļēāļĄāļ—āļĩāđˆāļžāļšāļšāđˆāļ­āļĒ

āđƒāļ„āļĢāļ„āļ·āļ­āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŦāđ‰āļēāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ MediciNova Inc?


āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŦāđ‰āļēāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ MediciNova Inc āđ„āļ”āđ‰āđāļāđˆ: Dr. Yuichi Iwaki, M.D., Ph.D.

āļĄāļĩāļāļĩāđˆāļŠāļ–āļēāļšāļąāļ™āļ—āļĩāđˆāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡ MediciNova Inc (MNOV)?


āļ“ āļ§āļąāļ™āļ—āļĩāđˆ 2026Q1 āļĄāļĩāļŠāļ–āļēāļšāļąāļ™āļˆāļģāļ™āļ§āļ™ 66 āđāļŦāđˆāļ‡āļ—āļĩāđˆāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡ MediciNova Inc āđ‚āļ”āļĒāļĄāļĩāļĄāļđāļĨāļ„āđˆāļēāļĢāļ§āļĄāļ›āļĢāļ°āļĄāļēāļ“ 6.15M āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 12.50% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ” āđ€āļĄāļ·āđˆāļ­āđ€āļ—āļĩāļĒāļšāļāļąāļšāļ§āļąāļ™āļ—āļĩāđˆ 2025Q4 āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™āđ„āļ”āđ‰āđ€āļžāļīāđˆāļĄāļ‚āļķāđ‰āļ™ 687606.00
tradingkey.logo
āļ„āļģāđ€āļ•āļ·āļ­āļ™āļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡: āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒāđāļĨāļ°āđāļ­āļ›āļžāļĨāļīāđ€āļ„āļŠāļąāļ™āļĄāļ·āļ­āļ–āļ·āļ­āļ‚āļ­āļ‡āđ€āļĢāļēāđƒāļŦāđ‰āļ‚āđ‰āļ­āļĄāļđāļĨāļ—āļąāđˆāļ§āđ„āļ›āđ€āļāļĩāđˆāļĒāļ§āļāļąāļšāļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļāļēāļĢāļĨāļ‡āļ—āļļāļ™āļšāļēāļ‡āļ›āļĢāļ°āđ€āļ āļ—āđ€āļ—āđˆāļēāļ™āļąāđ‰āļ™ Finsights āđ„āļĄāđˆāđ„āļ”āđ‰āđƒāļŦāđ‰āļ„āļģāđāļ™āļ°āļ™āļģāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļŦāļĢāļ·āļ­āļāļēāļĢāđāļ™āļ°āļ™āļģāļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļāļēāļĢāļĨāļ‡āļ—āļļāļ™āđƒāļ” āđ† āđāļĨāļ°āļāļēāļĢāđƒāļŦāđ‰āļ‚āđ‰āļ­āļĄāļđāļĨāļ”āļąāļ‡āļāļĨāđˆāļēāļ§āđ„āļĄāđˆāļ„āļ§āļĢāļ–āļđāļāļ•āļĩāļ„āļ§āļēāļĄāļ§āđˆāļēāđ€āļ›āđ‡āļ™āļāļēāļĢāđƒāļŦāđ‰āļ„āļģāđāļ™āļ°āļ™āļģāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļŦāļĢāļ·āļ­āļāļēāļĢāđāļ™āļ°āļ™āļģāđ‚āļ”āļĒ Finsights
āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļāļēāļĢāļĨāļ‡āļ—āļļāļ™āļĄāļĩāļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡āļ”āđ‰āļēāļ™āļāļēāļĢāļĨāļ‡āļ—āļļāļ™āļ­āļĒāđˆāļēāļ‡āļĄāļēāļ āļĢāļ§āļĄāļ–āļķāļ‡āļāļēāļĢāļŠāļđāļāđ€āļŠāļĩāļĒāđ€āļ‡āļīāļ™āļ•āđ‰āļ™āļ—āļĩāđˆāļĨāļ‡āļ—āļļāļ™āđ„āļ› āđāļĨāļ°āļ­āļēāļˆāđ„āļĄāđˆāđ€āļŦāļĄāļēāļ°āļŠāļģāļŦāļĢāļąāļšāļ—āļļāļāļ„āļ™ āļœāļĨāļāļēāļĢāļ”āļģāđ€āļ™āļīāļ™āļ‡āļēāļ™āđƒāļ™āļ­āļ”āļĩāļ•āļ‚āļ­āļ‡āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļāļēāļĢāļĨāļ‡āļ—āļļāļ™āđ„āļĄāđˆāđ„āļ”āđ‰āļšāđˆāļ‡āļšāļ­āļāļ–āļķāļ‡āļœāļĨāļāļēāļĢāļ”āļģāđ€āļ™āļīāļ™āļ‡āļēāļ™āđƒāļ™āļ­āļ™āļēāļ„āļ•
Finsights āļ­āļēāļˆāļ­āļ™āļļāļāļēāļ•āđƒāļŦāđ‰āļœāļđāđ‰āļĨāļ‡āđ‚āļ†āļĐāļ“āļēāļŦāļĢāļ·āļ­āļžāļąāļ™āļ˜āļĄāļīāļ•āļĢāļšāļļāļ„āļ„āļĨāļ—āļĩāđˆāļŠāļēāļĄāļ§āļēāļ‡āļŦāļĢāļ·āļ­āļŠāđˆāļ‡āđ‚āļ†āļĐāļ“āļēāļšāļ™āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒāļŦāļĢāļ·āļ­āđāļ­āļ›āļžāļĨāļīāđ€āļ„āļŠāļąāļ™āļĄāļ·āļ­āļ–āļ·āļ­āļ‚āļ­āļ‡āđ€āļĢāļēāļŦāļĢāļ·āļ­āļŠāđˆāļ§āļ™āđƒāļ”āļŠāđˆāļ§āļ™āļŦāļ™āļķāđˆāļ‡āļ‚āļ­āļ‡āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒāļŦāļĢāļ·āļ­āđāļ­āļ›āļžāļĨāļīāđ€āļ„āļŠāļąāļ™āļĄāļ·āļ­āļ–āļ·āļ­ āđāļĨāļ°āļ­āļēāļˆāđ„āļ”āđ‰āļĢāļąāļšāļ„āđˆāļēāļ•āļ­āļšāđāļ—āļ™āļˆāļēāļāļāļēāļĢāļ—āļĩāđˆāļ„āļļāļ“āļĄāļĩāļ›āļāļīāļŠāļąāļĄāļžāļąāļ™āļ˜āđŒāļāļąāļšāđ‚āļ†āļĐāļ“āļē
ÂĐ āļĨāļīāļ‚āļŠāļīāļ—āļ˜āļīāđŒ: FINSIGHTS MEDIA PTE. LTD. āļŠāļ‡āļ§āļ™āļĨāļīāļ‚āļŠāļīāļ—āļ˜āļīāđŒāļ—āļļāļāļ›āļĢāļ°āļāļēāļĢ